Literature DB >> 10120196

Cost-utility in practice: a policy maker's guide to the state of the art.

K Gerard1.   

Abstract

In recent years QALYs (quality adjusted life years) have achieved considerable fame or perhaps even notoriety in health services policy making. Yet little has been done to date to assess the potential benefit in policy terms of studies that have used cost-utility analysis (CUA). It was in recognition of this fact that this particular investigation was undertaken. An evaluation of 51 cost-utility studies is reported in the paper. Several criteria were applied to each study including aspects of technical and policy relevance. The main findings were: few studies had been undertaken; they were limited to few areas of health care; their technical execution was often of poor quality; the majority of studies used the empirical findings of health state valuations obtained from original developers of different quality of life techniques; and many claimed their results to be 'favourable' (i.e. efficient interventions). This claim, however, is misguided because individual results get fed into generalised QALY league tables which ignore the context of specific studies and use results not performed on a common basis. Consequently, the state of the applied art of CUA is currently open to considerable question.

Mesh:

Year:  1992        PMID: 10120196     DOI: 10.1016/0168-8510(92)90022-4

Source DB:  PubMed          Journal:  Health Policy        ISSN: 0168-8510            Impact factor:   2.980


  27 in total

Review 1.  Benefit valuation in economic evaluation of cancer therapies. A systematic review of the published literature.

Authors:  J Brown; M Sculpher
Journal:  Pharmacoeconomics       Date:  1999-07       Impact factor: 4.981

2.  Costs of diabetes. A methodological analysis of the literature.

Authors:  E Pagano; M Brunetti; F Tediosi; L Garattini
Journal:  Pharmacoeconomics       Date:  1999-06       Impact factor: 4.981

3.  Quality of economic evaluations in health care.

Authors:  Tom Jefferson; Vittorio Demicheli
Journal:  BMJ       Date:  2002-02-09

4.  Cost-per-QALY league tables: their role in pharmacoeconomic analysis.

Authors:  J M Mason
Journal:  Pharmacoeconomics       Date:  1994-06       Impact factor: 4.981

5.  Developing the QALY concept: exploring the problems of data acquisition.

Authors:  J Coast
Journal:  Pharmacoeconomics       Date:  1993-10       Impact factor: 4.981

Review 6.  The generalisability of pharmacoeconomic studies.

Authors:  J Mason
Journal:  Pharmacoeconomics       Date:  1997-06       Impact factor: 4.981

7.  Comments on economic evaluation of chemotherapy.

Authors:  S R Clausen; V Jøjnsson; M M Hansen; H Keiding; M Kjaer; B E Christensen; H Mouridsen; T Palshof; S W Hansen
Journal:  Pharmacoeconomics       Date:  1997-08       Impact factor: 4.981

8.  Guidelines for pharmacoeconomic studies. The ways forward.

Authors:  M F Drummond
Journal:  Pharmacoeconomics       Date:  1994-12       Impact factor: 4.981

Review 9.  The state of health economic evaluation research in Nigeria: a systematic review.

Authors:  Paul Gavaza; Karen L Rascati; Abiola O Oladapo; Star Khoza
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 10.  Cost of lung cancer: a methodological review.

Authors:  Laurent Molinier; Christophe Combescure; Cristos Chouaïd; Jean-Pierre Daurès; Bruno Housset; Didier Fabre; Alain Grand; Alain Vergnenègre
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.